Cargando…
Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
BACKGROUND: IncobotulinumtoxinA (Xeomin Cosmetic(®)) has been used previously in the management of masseteric hypertrophy. However, a standardized injection technique has not been established. The goal of the present study was to evaluate the efficacy and safety of two injection techniques in the ma...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047857/ https://www.ncbi.nlm.nih.gov/pubmed/30034247 http://dx.doi.org/10.2147/CCID.S164848 |
_version_ | 1783340002694922240 |
---|---|
author | Nikolis, Andreas Enright, Kaitlyn M Masouri, Sofia Bernstein, Steven Antoniou, Christina |
author_facet | Nikolis, Andreas Enright, Kaitlyn M Masouri, Sofia Bernstein, Steven Antoniou, Christina |
author_sort | Nikolis, Andreas |
collection | PubMed |
description | BACKGROUND: IncobotulinumtoxinA (Xeomin Cosmetic(®)) has been used previously in the management of masseteric hypertrophy. However, a standardized injection technique has not been established. The goal of the present study was to evaluate the efficacy and safety of two injection techniques in the management of masseteric hypertrophy using incobotulinumtoxinA. METHODS: Thirty female patients with masseteric hypertrophy were recruited and evenly randomized to receive bilateral treatments of either a single-injection technique (SIT) or a multiinjection technique (MIT). Improvement of masseteric hypertrophy was assessed at week 16 using standardized measurements and photographs. Patients completed a 5-point satisfaction questionnaire while physicians completed the Global Aesthetic Improvement Scale (GAIS) and 10-point photonumeric masseter prominence rating scale. RESULTS: There were no significant differences in physician ratings on the photonumeric scale and GAIS between the SIT and MIT groups. Results of the standardized measurements also revealed no significant difference between injection techniques. Majority of patients at every visit reported being “satisfied” with treatment results. Clinically, the number and severity of adverse events were similar between groups. CONCLUSION: This study supports the noninferiority of both SIT and MIT with regard to efficacy and safety in the management of masseteric hypertrophy, using incobotulinumtoxinA. |
format | Online Article Text |
id | pubmed-6047857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60478572018-07-20 Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques Nikolis, Andreas Enright, Kaitlyn M Masouri, Sofia Bernstein, Steven Antoniou, Christina Clin Cosmet Investig Dermatol Original Research BACKGROUND: IncobotulinumtoxinA (Xeomin Cosmetic(®)) has been used previously in the management of masseteric hypertrophy. However, a standardized injection technique has not been established. The goal of the present study was to evaluate the efficacy and safety of two injection techniques in the management of masseteric hypertrophy using incobotulinumtoxinA. METHODS: Thirty female patients with masseteric hypertrophy were recruited and evenly randomized to receive bilateral treatments of either a single-injection technique (SIT) or a multiinjection technique (MIT). Improvement of masseteric hypertrophy was assessed at week 16 using standardized measurements and photographs. Patients completed a 5-point satisfaction questionnaire while physicians completed the Global Aesthetic Improvement Scale (GAIS) and 10-point photonumeric masseter prominence rating scale. RESULTS: There were no significant differences in physician ratings on the photonumeric scale and GAIS between the SIT and MIT groups. Results of the standardized measurements also revealed no significant difference between injection techniques. Majority of patients at every visit reported being “satisfied” with treatment results. Clinically, the number and severity of adverse events were similar between groups. CONCLUSION: This study supports the noninferiority of both SIT and MIT with regard to efficacy and safety in the management of masseteric hypertrophy, using incobotulinumtoxinA. Dove Medical Press 2018-07-12 /pmc/articles/PMC6047857/ /pubmed/30034247 http://dx.doi.org/10.2147/CCID.S164848 Text en © 2018 Nikolis et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Nikolis, Andreas Enright, Kaitlyn M Masouri, Sofia Bernstein, Steven Antoniou, Christina Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques |
title | Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques |
title_full | Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques |
title_fullStr | Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques |
title_full_unstemmed | Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques |
title_short | Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques |
title_sort | prospective evaluation of incobotulinumtoxina in the management of the masseter using two different injection techniques |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047857/ https://www.ncbi.nlm.nih.gov/pubmed/30034247 http://dx.doi.org/10.2147/CCID.S164848 |
work_keys_str_mv | AT nikolisandreas prospectiveevaluationofincobotulinumtoxinainthemanagementofthemasseterusingtwodifferentinjectiontechniques AT enrightkaitlynm prospectiveevaluationofincobotulinumtoxinainthemanagementofthemasseterusingtwodifferentinjectiontechniques AT masourisofia prospectiveevaluationofincobotulinumtoxinainthemanagementofthemasseterusingtwodifferentinjectiontechniques AT bernsteinsteven prospectiveevaluationofincobotulinumtoxinainthemanagementofthemasseterusingtwodifferentinjectiontechniques AT antoniouchristina prospectiveevaluationofincobotulinumtoxinainthemanagementofthemasseterusingtwodifferentinjectiontechniques |